Fetal support tissue products and methods of use

Abstract

Methods of treating a complex wound by administering to a complex wound in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex wound. Methods of treating a complex lower extremity ulcer by administering to a complex lower extremity ulcer in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex lower extremity ulcer. Methods of reducing or preventing scar formation from granulation tissue by administering a fetal support tissue product to granulation tissue. Methods of repairing a spina bifida defect by administering to the defect in the individual a therapeutically effective amount of an umbilical cord product.

What is claimed is: 
     
         1 - 76 . (canceled) 
     
     
         77 . A method of repairing spina bifida defect in an individual in need thereof, comprising: administering to the individual a therapeutically effective amount of fetal support tissue product thereby repairing the spina bifida defect. 
     
     
         78 . The method of  claim 77 , wherein the spina bifida defect is a spina bifida cystica defect, a meningocele, or a meningomyelocele defect. 
     
     
         79 . The method of  claim 78 , wherein the spina bifida cystica defect is myeloschisis. 
     
     
         80 . The method of  claim 77 , wherein the individual is a fetus in utero. 
     
     
         81 . The method of  claim 77 , wherein the individual is a neonate. 
     
     
         82 . The method of  claim 77 , wherein the fetal support tissue product is a placental amniotic membrane product, umbilical cord product, umbilical cord amniotic membrane product, chorion, amnion-chorion product, placenta product, or any combination thereof. 
     
     
         83 . The method of  claim 82 , wherein the fetal support tissue product is an umbilical cord product. 
     
     
         84 . The method of  claim 83 , wherein the umbilical cord product further comprises Wharton’s Jelly. 
     
     
         85 . The method of  claim 83 , wherein the umbilical cord product is substantially free of blood. 
     
     
         86 . The method  claim 83 , wherein the umbilical cord product lacks an umbilical cord vein and umbilical cord arteries. 
     
     
         87 . The method of  claim 83 , wherein the umbilical cord product comprises umbilical cord amniotic membrane. 
     
     
         88 . The method of  claim 77 , wherein the administering comprises contacting the fetal support tissue product to the spina bifida defect site. 
     
     
         89 . The method of  claim 77 , wherein the repairing comprises regenerating epidermal, dermal, and subcutaneous layers of a spinal cord, meninges, and/or both, of the individual. 
     
     
         90 . The method of  claim 77 , wherein the administering is performed in utero. 
     
     
         91 . The method of  claim 88 , wherein the fetal support tissue product is administered within at least 48 hours after birth. 
     
     
         92 . The method of  claim 77 , wherein the fetal support tissue product is aseptically processed or terminally-sterilized. 
     
     
         93 . The method of  claim 77 , wherein the fetal support tissue product is lyophilized, ground, pulverized, morselized, a graft, a sheet, a powder, a gel, a homogenate, or an extract. 
     
     
         94 . The method of  claim 77 , wherein the fetal support tissue product is from a human. 
     
     
         95 . A method of reducing or preventing scar formation from granulation tissue in an individual in need thereof, comprising: administering to granulation tissue in the individual a therapeutically effective amount of a fetal support tissue product thereby reducing or preventing scar formation.